Mallinckrodt PLC Company Profile (NYSE:MNK)

About Mallinckrodt PLC (NYSE:MNK)

Mallinckrodt PLC logoMallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:MNK
  • CUSIP: N/A
  • Web:
  • Market Cap: $3.20691 billion
  • Outstanding Shares: 97,178,000
Average Prices:
  • 50 Day Moving Avg: $36.24
  • 200 Day Moving Avg: $41.42
  • 52 Week Range: $31.51 - $68.43
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 4.02
  • P/E Growth: 0.84
Sales & Book Value:
  • Annual Revenue: $3.27 billion
  • Price / Sales: 0.96
  • Book Value: $52.46 per share
  • Price / Book: 0.62
  • EBITDA: $666.6 million
  • Net Margins: 12.64%
  • Return on Equity: 15.28%
  • Return on Assets: 5.20%
  • Debt-to-Equity Ratio: 1.05%
  • Current Ratio: 1.06%
  • Quick Ratio: 0.81%
  • Average Volume: 2.51 million shs.
  • Beta: 1.51
  • Short Ratio: 7.62

Frequently Asked Questions for Mallinckrodt PLC (NYSE:MNK)

What is Mallinckrodt PLC's stock symbol?

Mallinckrodt PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt PLC's stock buyback program work?

Mallinckrodt PLC announced that its board has authorized a share repurchase program on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 18.5% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's board believes its stock is undervalued.

How were Mallinckrodt PLC's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) posted its earnings results on Tuesday, August, 8th. The company reported $1.85 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.73 by $0.12. The firm earned $824.50 million during the quarter, compared to analysts' expectations of $829.56 million. Mallinckrodt PLC had a net margin of 12.64% and a return on equity of 15.28%. The company's quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the company earned $2.03 earnings per share. View Mallinckrodt PLC's Earnings History.

When will Mallinckrodt PLC make its next earnings announcement?

Mallinckrodt PLC is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Mallinckrodt PLC.

What guidance has Mallinckrodt PLC issued on next quarter's earnings?

Mallinckrodt PLC issued an update on its FY17 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of $7.40-8.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.53.

Where is Mallinckrodt PLC's stock going? Where will Mallinckrodt PLC's stock price be in 2017?

17 equities research analysts have issued 12 month target prices for Mallinckrodt PLC's stock. Their forecasts range from $40.00 to $98.00. On average, they expect Mallinckrodt PLC's stock price to reach $59.97 in the next year. View Analyst Ratings for Mallinckrodt PLC.

What are analysts saying about Mallinckrodt PLC stock?

Here are some recent quotes from research analysts about Mallinckrodt PLC stock:

  • 1. According to Zacks Investment Research, "Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures to transform the portfolio and become a high-performing specialty pharmaceutical company. The company sold its Nuclear Imaging business and Intrathecal Therapy business to focus on its key areas. While Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments, sales of Therakos is expected to decline. The generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. The company expects double-digit declines in revenues from this segment. Shares of the company have underperformed the industry so far in 2017." (10/17/2017)
  • 2. Mizuho analysts commented, "We reiterate our Buy rating and $73 PT and push back against short-seller inaccuracies and Acthar pricing concerns." (5/31/2017)
  • 3. Guggenheim analysts commented, "Although any potential competition for MNK's largest single drug, Acthar, is a concern, we think that it will take at least several years for Marathon to even establish proof of concept for its product, which means there is no near-to-mid-term threat here. We forecast Acthar sales of $1.2B in '16 and total MNK sales of $3.3B. We believe that MNK's execution of its stated business objectives is underappreciated and would note that the company has a demonstrated record of success, supported by consistent earnings beats over the last five quarters. We continue to believe strong execution of MNK's growth initiatives will drive P/E multiple expansion (from 6x to at least 10x, average pharma trough multiple) and put MNK shares back on a path to $70+." (1/19/2017)

Who are some of Mallinckrodt PLC's key competitors?

Who are Mallinckrodt PLC's key executives?

Mallinckrodt PLC's management team includes the folowing people:

  • Melvin D. Booth Ph.D., CPA, Independent Chairman of the Board
  • Mark C. Trudeau, President, Chief Executive Officer, Director
  • Matthew K. Harbaugh, Chief Financial Officer, Executive Vice President
  • Ian J. Watkins, Chief Human Resource Officer
  • Ronald K. Lloyd, Executive Vice President and President - Hospital Therapies
  • Gary M. Phillips M.D., Executive Vice President and Chief Strategy Officer
  • Steven Romano, Executive Vice President and Chief Scientific Officer
  • Frank Scholz, Executive Vice President of Global Operations and President - Specialty Generics
  • Hugh O'Neill, Senior Vice President and President - Autoimmune and Rare Diseases
  • Raymond J. Furey, Chief Compliance Officer

How do I buy Mallinckrodt PLC stock?

Shares of Mallinckrodt PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mallinckrodt PLC's stock price today?

One share of Mallinckrodt PLC stock can currently be purchased for approximately $32.36.

MarketBeat Community Rating for Mallinckrodt PLC (NYSE MNK)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  564 (Vote Outperform)
Underperform Votes:  298 (Vote Underperform)
Total Votes:  862
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mallinckrodt PLC (NYSE:MNK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.76)
Consensus Price Target: $59.97 (85.32% upside)
Consensus Price Target History for Mallinckrodt PLC (NYSE:MNK)
Price Target History for Mallinckrodt PLC (NYSE:MNK)
Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/15/2017MizuhoReiterated RatingHold$40.00N/AView Rating Details
10/6/2017Stifel NicolausReiterated RatingBuyN/AView Rating Details
10/6/2017Jefferies Group LLCReiterated RatingBuy$60.00N/AView Rating Details
10/5/2017Piper Jaffray CompaniesReiterated RatingBuy$67.00N/AView Rating Details
10/4/2017Canaccord GenuityDowngradeBuy -> Hold$77.00 -> $40.00N/AView Rating Details
10/2/2017Cantor FitzgeraldSet Price TargetBuy$52.00MediumView Rating Details
9/28/2017Goldman Sachs Group, Inc. (The)Initiated CoverageBuy -> Buy$55.00MediumView Rating Details
9/19/2017Oppenheimer Holdings, Inc.Lower Price Target$70.00 -> $48.00LowView Rating Details
9/14/2017Deutsche Bank AGReiterated RatingBuy$56.00 -> $45.00LowView Rating Details
9/14/2017Citigroup Inc.Lower Price TargetReduce -> Buy$45.00LowView Rating Details
9/6/2017Morgan StanleyDowngradeOverweight -> Equal Weight$65.00 -> $40.00LowView Rating Details
8/9/2017BMO Capital MarketsReiterated RatingOutperform$69.00 -> $65.00LowView Rating Details
8/9/2017Raymond James Financial, Inc.Lower Price TargetOutperform$65.00 -> $58.00LowView Rating Details
6/21/2017Wells Fargo & CompanyReiterated RatingOutperform$83.50HighView Rating Details
4/1/2017GuggenheimSet Price TargetBuy$98.00LowView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformLowView Rating Details
1/25/2017J P Morgan Chase & CoSet Price TargetHold$78.00N/AView Rating Details
8/25/2016Barclays PLCReiterated RatingOverweight$88.00N/AView Rating Details
3/16/2016Northland SecuritiesReiterated RatingBuy$95.00N/AView Rating Details
2/2/2016NomuraReiterated RatingNeutral$100.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Mallinckrodt PLC (NYSE:MNK)
Earnings by Quarter for Mallinckrodt PLC (NYSE:MNK)
Earnings History by Quarter for Mallinckrodt PLC (NYSE MNK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017$1.82N/AView Earnings Details
8/8/2017Q2 2017$1.73$1.85$829.56 million$824.50 millionViewListenView Earnings Details
5/8/2017Q1 2017$1.63$1.68$781.23 million$810.90 millionViewListenView Earnings Details
2/7/2017Q117$1.82$1.91$827.12 million$829.90 millionViewListenView Earnings Details
11/29/2016Q416$1.98$2.04$880.10 million$887.20 millionViewListenView Earnings Details
8/2/2016Q316$2.01$2.20$920.35 million$970.60 millionViewListenView Earnings Details
5/3/2016Q216$1.72$2.01$878.70 million$918.00 millionViewListenView Earnings Details
2/2/2016Q116$1.78$2.09$888.33 million$915.00 millionViewListenView Earnings Details
11/23/2015Q415$1.77$1.84$869.41 million$882.40 millionViewListenView Earnings Details
8/4/2015Q315$1.82$2.05$983.81 million$965.10 millionViewListenView Earnings Details
5/5/2015Q215$1.48$1.72$860.89 million$909.90 millionViewListenView Earnings Details
2/3/2015Q115$1.57$1.84$880.12 million$866.00 millionViewListenView Earnings Details
11/19/2014Q414$1.41$1.68$759.04 million$789.00 millionViewListenView Earnings Details
8/7/2014Q314$0.86$1.20$278.80 million$653.10 millionViewListenView Earnings Details
5/8/2014Q214$0.79$0.95$566.50 million$557.80 millionViewListenView Earnings Details
2/6/2014Q1$0.66$0.88$539.24 million$540.20 millionViewListenView Earnings Details
11/7/2013$0.85$1.02$572.57 million$552.20 millionViewListenView Earnings Details
8/9/2013Q3 2013$0.78$0.49$557.22 million$570.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)
2017 EPS Consensus Estimate: $7.48
2018 EPS Consensus Estimate: $8.27
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.54$1.84$1.71
Q2 20173$1.70$1.95$1.80
Q3 20173$1.81$1.89$1.86
Q4 20173$1.95$2.35$2.11
Q1 20183$1.61$1.82$1.70
Q2 20182$1.91$2.15$2.03
Q3 20182$2.03$2.10$2.07
Q4 20182$2.48$2.48$2.48
(Data provided by Zacks Investment Research)


Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Mallinckrodt PLC (NYSE:MNK)
Insider Ownership Percentage: 0.53%
Institutional Ownership Percentage: 97.36%
Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)
Institutional Ownership by Quarter for Mallinckrodt PLC (NYSE:MNK)
Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/30/2017Meredith B. FischerInsiderBuy1,280$39.63$50,726.40View SEC Filing  
6/9/2017Steven J. RomanoVPBuy1,000$39.88$39,880.00View SEC Filing  
6/8/2017Hugh M. O'neillVPBuy1,000$40.24$40,240.00View SEC Filing  
6/5/2017Coleman N Lannum IIIVPBuy500$39.33$19,665.00View SEC Filing  
6/2/2017Coleman N Lannum IIIVPBuy1,350$42.89$57,901.50View SEC Filing  
5/12/2017Coleman N. Lannum IIIVPBuy1,968$46.20$90,921.60View SEC Filing  
3/10/2017Matthew K. HarbaughCFOBuy600$49.19$29,514.00View SEC Filing  
3/7/2017Michael-Bryant HicksGeneral CounselBuy290$50.35$14,601.50View SEC Filing  
2/23/2017Meredith B. FischerInsiderBuy2,000$54.34$108,680.00View SEC Filing  
2/14/2017Mark TrudeauInsiderBuy1,000$50.47$50,470.00View SEC Filing  
2/10/2017Steven J. RomanoVPBuy1,000$49.68$49,680.00View SEC Filing  
5/10/2016Hugh M O'neillVPBuy1,653$60.99$100,816.47View SEC Filing  
5/10/2016Matthew K HarbaughCFOBuy500$59.37$29,685.00View SEC Filing  
5/6/2016Mark TrudeauCEOBuy1,000$56.02$56,020.00View SEC Filing  
5/6/2016Steven J RomanoVPBuy900$56.00$50,400.00View SEC Filing  
3/4/2016Coleman N Lannum IIIVPBuy2,600$62.63$162,838.00View SEC Filing  
2/26/2016Meredith B FischerVPBuy1,400$69.80$97,720.00View SEC Filing  
2/12/2016Coleman N Lannum IIIVPBuy600$59.66$35,796.00View SEC Filing  
2/10/2016Coleman N Lannum IIIVPBuy1,300$62.58$81,354.00View SEC Filing  
2/9/2016Matthew K. HarbaughCFOBuy1,300$63.00$81,900.00View SEC Filing  
2/8/2016Coleman N. Lannum IIIVPBuy800$66.37$53,096.00View SEC Filing  
12/22/2015Coleman N Lannum IIISVPBuy500$72.50$36,250.00View SEC Filing  
12/11/2015Terrance L CarlsonGeneral CounselBuy1,000$69.10$69,100.00View SEC Filing  
12/2/2015Gary M. PhillipsVPBuy1,000$72.17$72,170.00View SEC Filing  
11/30/2015Mark TrudeauCEOBuy1,350$65.89$88,951.50View SEC Filing  
11/27/2015Coleman N Lannum IIISVPBuy1,200$66.86$80,232.00View SEC Filing  
11/27/2015Meredith B FischerVPBuy2,200$66.93$147,246.00View SEC Filing  
11/27/2015Terrance L CarlsonGeneral CounselBuy1,000$66.54$66,540.00View SEC Filing  
8/25/2015Hugh M O'neillSVPBuy1,197$83.52$99,973.44View SEC Filing  
8/25/2015Mark TrudeauCEOBuy1,000$83.08$83,080.00View SEC Filing  
8/21/2015Coleman N Lannum IIISVPBuy2,375$88.52$210,235.00View SEC Filing  
8/21/2015Mark TrudeauCEOBuy2,000$88.45$176,900.00View SEC Filing  
6/4/2015Coleman N Lannum IIIVPBuy1,300$126.41$164,333.00View SEC Filing  
6/2/2015Matthew K HarbaughCFOSell22,106$128.64$2,843,715.84View SEC Filing  
5/18/2015Mario D SaltarelliVPSell4,580$127.44$583,675.20View SEC Filing  
5/13/2015Don M BaileyDirectorSell51,417$122.45$6,296,011.65View SEC Filing  
5/11/2015Sandra L HattenVPSell2,024$122.29$247,514.96View SEC Filing  
4/13/2015Don M BaileyDirectorSell40,000$127.61$5,104,400.00View SEC Filing  
3/13/2015Don M BaileyDirectorSell40,000$123.40$4,936,000.00View SEC Filing  
2/13/2015Don M BaileyDirectorSell33,891$114.63$3,884,925.33View SEC Filing  
2/2/2015Mark TrudeauCEOSell11,925$105.94$1,263,334.50View SEC Filing  
1/9/2015Mark TrudeauCEOSell15,720$102.00$1,603,440.00View SEC Filing  
12/22/2014Peter G EdwardsVPSell1,265$99.69$126,107.85View SEC Filing  
12/18/2014Mark TrudeauCEOSell13,831$93.59$1,294,443.29View SEC Filing  
9/10/2014Raymond J FureyVPSell5,441$85.90$467,381.90View SEC Filing  
9/8/2014Don M BaileyDirectorSell221,177$85.23$18,850,915.71View SEC Filing  
9/5/2014Raymond J FureyVPSell15,000$85.47$1,282,050.00View SEC Filing  
9/5/2014Virgil D ThompsonDirectorSell25,000$83.76$2,094,000.00View SEC Filing  
9/2/2014Raymond J FureyVPSell10,303$81.61$840,827.83View SEC Filing  
8/29/2014Raymond J FureyVPSell4,840$80.90$391,556.00View SEC Filing  
8/19/2014Joseph A ZaccagninoDirectorBuy3,000$71.06$213,180.00View SEC Filing  
8/13/2014Paulson & Co IncMajor ShareholderBuy132,100$69.80$9,220,580.00View SEC Filing  
8/12/2014J Martin CarrollDirectorBuy2,000$69.24$138,480.00View SEC Filing  
8/12/2014Paulson & Co IncMajor ShareholderBuy467,900$68.78$32,182,162.00View SEC Filing  
8/11/2014Paulson & Co IncMajor ShareholderBuy207,900$69.70$14,490,630.00View SEC Filing  
8/7/2014Paulson & Co IncMajor ShareholderBuy700,200$70.15$49,119,030.00View SEC Filing  
8/1/2014Paulson & Co IncMajor ShareholderBuy275,000$69.60$19,140,000.00View SEC Filing  
6/11/2014Melvin D BoothDirectorBuy4,000$76.05$304,200.00View SEC Filing  
5/9/2014Paulson & Co Incmajor shareholderBuy786,207$73.63$57,888,421.41View SEC Filing  
2/3/2014Mark TrudeauCEOSell14,890$56.12$835,626.80View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Mallinckrodt PLC (NYSE:MNK)
Latest Headlines for Mallinckrodt PLC (NYSE:MNK)
DateHeadline logoMallinckrodt PLC (MNK) Downgraded by Zacks Investment Research - October 17 at 2:52 PM logoThe Final Straw For Mallinckrodt? - Seeking Alpha - October 16 at 11:15 PM logoMallinckrodt Opens Specialty Brands Office In New Jersey, Announces $100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students - October 16 at 11:15 PM logoReviewing Mallinckrodt PLC (MNK) & Its Competitors - October 16 at 12:32 PM logoMallinckrodt PLC (MNK) & Its Rivals Head to Head Analysis - October 16 at 9:04 AM logoMallinckrodt PLC's (MNK) "Hold" Rating Reiterated at Mizuho - October 15 at 7:56 AM logoMallinckrodt PLC (MNK) versus The Competition Head to Head Comparison - October 14 at 12:46 AM logoMallinckrodt PLC (MNK) Expected to Earn FY2018 Earnings of $8.34 Per Share - October 12 at 1:54 PM logoMallinckrodt PLC (MNK) Receives Consensus Rating of "Buy" from Brokerages - October 12 at 6:12 AM logoDARA Biosciences (DARA) vs. Mallinckrodt PLC (MNK) Head to Head Analysis - October 11 at 4:30 PM logoAnalysts Issue Forecasts for Mallinckrodt PLC's Q3 2017 Earnings (MNK) - October 11 at 6:32 AM logoMallinckrodt to Begin Sarcoidosis Study on Acthar Gel - - Nasdaq - October 10 at 11:52 PM logoMallinckrodt plc to Report Earnings Results for Third Quarter of Fiscal 2017 - PR Newswire (press release) - October 10 at 11:52 PM logoMallinckrodt plc to Report Earnings Results for Third Quarter of Fiscal 2017 - October 10 at 11:52 PM logoMallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis - October 9 at 8:22 PM logoMallinckrodt (MNK) Plans Phase 4 Trial of HP Acthar Gel for Symptomatic Sarcoidosis - - October 9 at 3:20 PM logoMallinckrodt PLC (MNK) and TherapeuticsMD (TXMD) Critical Contrast - October 8 at 6:30 AM logoMallinckrodt PLC (MNK) Earns Buy Rating from Stifel Nicolaus - October 6 at 4:52 PM logoMallinckrodt plc Discusses Pipeline Transformation, Company Outlook at Investor Briefing - PR Newswire (press release) - October 6 at 10:41 AM logoMallinckrodt PLC (MNK) Earns Buy Rating from Jefferies Group LLC - October 6 at 9:36 AM logoMallinckrodt PLC (MNK) Given a $70.00 Price Target at UBS AG - October 6 at 9:12 AM logoMallinckrodt PLC (MNK) Rating Lowered to Hold at Canaccord Genuity - October 4 at 9:14 PM logoMallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy - Nasdaq - October 4 at 8:33 AM logoMallinckrodt Details Development Pipeline Highlights - Quick Facts - Nasdaq - October 4 at 8:33 AM logoMallinckrodt PLC (MNK) PT Set at $52.00 by Cantor Fitzgerald - October 2 at 4:30 PM logoMallinckrodt (MNK) Announces Agreement to License Inhaled Xenon Gas Therapy Development Product - - October 2 at 11:45 AM logoMallinckrodt Licenses Inhaled Xenon Gas Therapy Development Product - October 2 at 11:45 AM logoMallinckrodt PLC (MNK) Now Covered by Analysts at Goldman Sachs Group, Inc. (The) - September 28 at 6:20 PM logoETFs with exposure to Mallinckrodt Plc : September 25, 2017 - September 25 at 7:28 PM logoMallinckrodt Completes Acquisition of InfaCare Pharmaceutical Corporation and Stannsoporfin, its Proprietary Therapy in Late-Stage Development for Newborns at Risk for Severe Jaundice - September 25 at 7:28 PM logoMallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United States - September 23 at 8:17 AM logoOppenheimer Holdings Brokers Decrease Earnings Estimates for Mallinckrodt PLC (MNK) - September 21 at 1:44 PM logoInteresting MNK Put And Call Options For November 17th - Nasdaq - September 20 at 6:23 AM logoMallinckrodt Announces Election Of David Norton To Its Board Of Directors - September 20 at 6:23 AM logoMallinckrodt PLC (MNK) Price Target Lowered to $48.00 at Oppenheimer Holdings, Inc. - September 19 at 3:52 PM logoBreakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Horizon ... - September 18 at 11:02 PM logoBreakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Horizon Pharma, Mylan, and Neurocrine Biosciences - September 18 at 11:02 PM logoMallinckrodt PLC (MNK) and Its Competitors Head to Head Contrast - September 18 at 4:28 AM logoMallinckrodt PLC (MNK) Receives Consensus Recommendation of "Buy" from Analysts - September 17 at 6:38 AM logoPiper Jaffray Companies Reaffirms Buy Rating for Mallinckrodt PLC (MNK) - September 15 at 5:32 PM logoMallinckrodt (MNK): Cutting PT After Negative Ruling - Deutsche Bank - - September 14 at 9:08 PM logoETFs with exposure to Mallinckrodt Plc : September 14, 2017 - September 14 at 9:08 PM logoMallinckrodt PLC (MNK) Given Buy Rating at Deutsche Bank AG - September 14 at 3:32 PM logoMallinckrodt PLC (MNK) PT Lowered to $45.00 at Citigroup Inc. - September 14 at 9:34 AM logoMizuho Securities Downgrades Mallinckrodt plc (MNK) to Neutral, Negatively Revises EPS Estimates - September 14 at 7:51 AM logoMallinckrodt Plc :MNK-US: Earnings Analysis: Q3, 2017 By the Numbers : September 13, 2017 - September 14 at 7:51 AM logoMallinckrodt PLC (MNK) Downgraded by Mizuho - September 13 at 8:05 AM logoThe most respected medical journal in the US just eviscerated a drug that's cost taxpayers over $1 billion - September 13 at 6:38 AM logoMallinckrodt PLC (MNK) Downgraded by Morgan Stanley - September 10 at 7:34 PM logoMallinckrodt PLC's (MNK) Buy Rating Reaffirmed at Stifel Nicolaus - September 10 at 7:02 PM



Mallinckrodt PLC (MNK) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.